Update on adjuvant treatment of colorectal cancer

Current Opinion in Oncology

Volumn 10, Issue 4, 1998, Pages 367-374

  Stewart, Josephine M ^a   Zalcberg, John R ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; OXALIPLATIN; RALTITREXED; TEGAFUR; URACIL;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; PORTAL VEIN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECTUM CANCER; SURVIVAL TIME;

EID: 0031878308     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199807000-00015     Document Type: Article

References (64)

1. Laurie JA, Moertel CG, Fleming TR, Wieland HS, Leigh JE, Rubin J, et al.: Surgical adjuvant treatment of large bowel cancer: an evaluation of levamisole and the combination of levamisole and 5-FU. A study of the North Central Cancer Treatment Group (NCCTG) and the Mayo Clinic. J Clin Oncol 1989, 7:1447-1456.
2. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Goodman PJ, et al.: Levamisole and fluorouracil for adjuvant treatment of resected colorectal cancer. N Engl J Med 1990, 322:352-358.
3. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
4. Buyse M, Piedbois P, Rustum Y: Advanced Colorectal Cancer Analysis Project. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896-903.
5. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345:939-944.
6. O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haler DG, Mayer RJ, Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250. The final results of an Intergroup study confirming a survival benefit with 6 months of adjuvant therapy with intensive course of 5-FU/leucovorin in patients with colon cancer.
7. Zaniboni A: Adjuvant chemotherapy in colorectal cancer with high-dose leucovonn and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 1997, 15:2432-2441.
8. Dube S, Heyen F, Jenicek M: Adjuvant chemotherapy in colorectal carcinoma. Results of a meta-analysis. Dis Colon Rectum 1997, 40:35-41. A careful qualitative and quantitative meta-analysis of 39 randomized trials of adjuvant chemotherapy in colorectal cancer. A survival benefit was found for patients with colorectal cancer who receive adjuvant chemotherapy.
9. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, et al.: A prospective, randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal cancer. J Clin Oncol 1987, 5:1559-1565.
10. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J, et al.: The relative efficacy of 5-FU+leucovorin (FU-LV)+levamisole (FU-LV-LEV) in patients with Dukes B and C carcinoma of the colon: first report of NSABP C-04 [abstract 460]. Proc Am Soc Clin Oncol 1996, 15:205.
11. Haller DG, Catalano PJ, MacDonald JS, Mayer RJ: Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089 [abstract]. Proc Am Soc Clin Oncol 1997, 16:265a. Although the results are not final, this important study suggests that 6 months of adjuvant therapy with 5-FU/leucovorin for high-risk stage II and III colon cancer is at least as effective as 12 months of 5-FU/levamisole.
12. Peretz T, Figer A, Borovik R, Steiner M, Catane R, Sulkes A, Shani A: 5-FU + leucovorin (LV) as active and less toxic regimen than 5-FU + levamisole (LM) in the adjuvant therapy of colorectal cancer-Israel Cooperative Oncology Group [abstract 941]. Proc Am Soc Clin Oncol 1997, 16:265a.
13. Hartung G, Maas K, Edler L, Diezler P, Hagmuller E, Pastemak L, et al.: Adjuvant chemotherapy of Dukes C colon carcinoma: comparison of 5-FU + levamisole (LEV) 12 months versus 5-FU + folinic acid (FA) 12 months vs 5-FU + FA 6 months [abstract 751]. Eur J Cancer 1997, 33:168.
14. Taylor I, Machin D, Mullee M, Trotter G, Cooke T, West C: A randomized controlled trial of adjuvant portal vein cytotoxic infusion in colorectal cancer. Br J Surg 1985, 72:359-363.
15. Wolmark N, Rockette H, Wickerman DL, Fisher B, Redmond C, Fisher ER, et al.: Adjuvant therapy of Dukes A, B and C adenocarcinoma of the colon with portal vein 5-FU hepatic infusion: preliminary results of NSABP protocol C-02. J Clin Oncol 1990, 8:1466-1475.
16. Gray R, James R, Mossman J, Stenning S: AXIS-a suitable case for treatment. Br J Cancer 1989, 63:841-845.
17. Nitti D, Wils J, Sahmoud T, Curran D, Couvreur ML, Lise M, et al.: Final results of a phase III clinical trial on adjuvant intraportal infusion with heparin and 5-fluorouracil (5-FU) in resectable colon cancer (EORTC GITCCG 1983-1987) Eur J Cancer 1997, 33:1209-1215. This randomized study of 235 patients with resectable colon cancer again demonstrates the safety and tolerable toxicity of adjuvant intraportal 5-FU and heparin, but failed to show a benefit in 5-year DFS or OS compared with control patients.
18. Bury J, Focan C, Beauduin M, Herman ML, Vindevoghel A, Lecomte M, et al.: Portal and systemic chemotherapy for Dukes B2 and C colorectal cancer. An intermediary report on a double randomised trial [abstract 942]. Proc Am Soc Clin Oncol 1997, 16:266a.
19. Liver Infusion Meta-Analysis Group: Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997, 89:497-505. This meta-analysis involving over 4000 patients with colorectal cancer from 10 studies concludes that adjuvant portal vein chemotherapy may produce a small survival benefit compared with untreated control patients, but that additional evidence from large randomized trials is needed.
20. Mayer RJ: Does adjuvant therapy work in colon cancer? N Engl J Med 1990, 322:399-401.
21. Wolmark N, Rockette H, Fisher B, Wickerman DL, Redmond C, Fisher ER, et al.: The benefit of leucovorin modulated 5-fluorouracil as post operative adjuvant treatment for primary colon cancer: results from the National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879-1888.
22. Mamounas EP, Rochette H, Jones J, Wieland S, Wickerman DL, Fisher B, Wolmark N: Comparative efficacy of adjuvant chemotherapy in patients with Dukes B versus Dukes C colon cancer: results from 4 NSABP adjuvant studies (CO1, CO2, CO3, CO4) [abstract 461]. Proc Am Soc Clin Oncol 1996, 15:205.
23. Erlichman C, Marsoni S, Seitz JF, Skillings J, Shepard L, Zee B, et al.: Event free overall survival is increased by FUFA in resected B colon cancer: a pooled analysis of five randomised trials (RCTS) [abstract 991]. Proc Am Soc Clin Oncol 1997, 16:280a. This pooled analysis of almost 1000 patients, which demonstrates a survival benefit in patients with stage II colon cancer receiving 5-FU/leucovorin, indicates that there is likely to be a role for adjuvant chemotherapy in this group of patients.
24. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, et al.: Phase II trial of uracil and tegafur plus oral leucovorin, an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994, 12:2296-2300.
25. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, et al.: A fixed ratio combination of uracil and Ftorafur (UFT) with low-dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 1995, 75:782-785.
26. Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y: A meta-analysis of adjuvant therapy using oral fluoropyrimidines in patients with curatively resected colorectal carcinoma [abstract 943]. Proc Am Soc Clin Oncol 1997, 16:266a.
27. Findlay M, Van Cutsem E, Kocha W, Allman D. Laffranchi B, Griffin T, et al.: A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer [abstract 798]. Proc Am Soc Clin Oncol 1997, 16:227a.
28. Van Cutsem E: A glimpse of the future. New directions in the treatment of colorectal cancer. Eur J Cancer 1996, 23A:(Supplement 5):S23-S27.
29. Riethmuller G, Holz E, Schlimok G. et al.: Monoclonal antibody (MAB) adjuvant therapy of Dukes C colorectal carcinoma: 7-year update of a prospective randomized trial [abstract 1385]. Proc Am Soc Clin Oncol 1996, 15:444.
30. Hoover HC, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a phase II prospectively randomised trial. J Clin Oncol 1993, 11:390-399.
31. Vermorken JB, Claessen A, Gall H, van Holten A, van Tinteren, Meijer S, et al.: Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Dukes B2, B3 or C colon cancer [abstract 722]. Eur J Cancer 1997, 33:s162.
32. Swedish rectal cancer trial: Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997, 336:980-987. This landmark study that randomly assigned 1168 patients with resectable rectal cancer to receive either preoperative radiotherapy or surgery alone is the first to show a survival benefit for patients receiving adjuvant radiotherapy. Importantly, postoperative mortality was not increased in the radiotherapy group.
33. Medical Research Council Rectal Cancer Working Party: Randomized trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum Lancet 1996, 348:1610-1614.
34. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC: Adjuvant therapy of rectal cancer: why we still don't know. JAMA 1988 259:3571-3578.
35. Minsky BD: Adjuvant therapy for rectal cancer - a good first step. N Engl J Med 1997, 336:1016-1018.
36. Holm T, Rutqvist LE, Johansson H, Cedermark B: Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: causes and risk factors. Br J Surg 1996, 83:964-968.
37. Arnaud JP, Nordlinger B, Bosset JF, Boes GH, Sahmoud T, Schlag PM, Pene F: Radical surgery and postoperative radiotherapy as combined treatment in rectal cancer. Final results of a phase III study of the European Organization for Research and Treatment of Cancer. Br J Surg 1997, 84:352-357.
38. Frykholm GJ, Glimelius B, Pahlman L: Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and evaluation of late secondary effects. Dis Colon Rectum 1993, 66:49-55.
39. Glimelius B, Isacsson U, Jung B, Pahlman L: Radiotherapy in addition to radical surgery in rectal cancer: evidence for a dose-response effect favouring preoperative treatment. Int J Radiat Oncol Biol Phys 1997, 37:281-287. A thorough and interesting analysis from the Uppsala group of all randomized trials initiated before 1988 comparing preoperative or postoperative radiotherapy to surgery alone. It suggests that preoperative treatment may be more dose-efficient than postoperative treatment, potentially reducing both acute and delayed toxicity.
40. Sjodahl R: Do we need adjuvant treatment for rectal cancer? Ann Med 1997, 29:91-93.
41. Enker WE: Total mesorectal excision-the new gold standard of surgery for rectal cancer. Ann Med 1997, 29:127-133.
42. Gastrointestinal Tumor Study Group: Prolongation of disease-free survival in surgically treated rectal carcinoma. N Engl J Med 1985, 312:1465-1472.
43. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Schmiegel W, Raab R, Hoffken K, et al.: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991, 324:709-715.
44. Tepper J, O'Connell MJ, Petroni GR, Mollis D, Cooke E, Benson AB, et al.: Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. J Clin Oncol 1997, 15:2030-2039. This large intergroup study comparing three chemoradiation schedules in patients with resected rectal cancer strongly suggests that levamisole is unlikely to have any additional benefit over 5-FU alone in this setting. The role of the addition of leucovorin to 5-FU can be determined only with longer follow-up.
45. O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, et al.: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994, 331:502-507.
46. Kim HK, Jessup JM, Beard CJ, Bornstein B, Cady B, Stone MD, et al.: Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection and intraoperative radiation therapy. Int J Radiat Oncol Biol Phys 1997, 88:777-783.
47. Chan AKP, Wong AO, Langevin JM, Jenken DA, Khoo R, Heine JA, et al.: "Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival. Int J Radiat Oncol Biol Phys 1997, 37:629-637.
48. Gunderson LL, Nelson H, Martenson JA, Cha S, Haddock MG, Devine RM, et al.: Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/-5 FU. Int J Radiat Oncol Biol Phys 1997, 37:601-614.
49. Azinovic I, Calvo F, Santos M, Aristu J, Martinez-Monge R, Ortiz de Urbina D: Intense local therapy in primary rectal cancer: multi-institutional results with preoperative chemoradiation therapy plus IORT. Front Radiat Ther Oncol 1997, 31:196-199.
50. Eble MJ, Lehnert T, Herfath C, Wannenmacher M: IORT as adjuvant treatment in primary rectal carcinomas: multi-modality treatment. Front Radiat Ther Oncol 1997, 31:200-203.
51. Azinovic I, Calvo F, Santos M, Aristu J Martinez-Monge R, Ortiz de Urbina D: IORT in primary rectal cancer (T3-4Nx): multi-institutional experience with conventional treatment sequence. Front Radiat Ther Oncol 1997, 31:193-195.
52. Farouk R, Nelson H, Gunderson LL: Aggressive multimodality treatment for locally advanced irresectable rectal cancer. Br J Surg 1997, 84:741-749.
53. Lundby L, Jensen VJ, Overgaard J, Layrberg S: Long-term colorectal function after postoperative radiotherapy for colorectal cancer [letter]. Lancet 1997, 350:564. This article presents the results of a detailed telephone survey of patients treated for rectal cancer with postoperative radiotherapy, which suggest delayed toxicity with this treatment.
54. Ratto C, Sofo L, Valentini V, Genovesi D, Morganti AG, Verna L, et al.: Late effects of integrated therapies, including IORT, on lumbosacral plexus and anorectal physiology in patients treated for rectal cancer. Front Radiat Ther Oncol 1997, 31:41-44.
55. Norum J, Vonen B, Olsen JA, Revhaug A: Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes B and C colorectal carcinoma. An analysis. Ann Oncol 1997, 8:65-70. Despite the seemingly small survival benefit seen with adjuvant chemotherapy in colorectal cancer, this analysis is able to demonstrate its cost effectiveness in terms of both money spent and quality of life.
56. Dunlop MG: Science, medicine and the future. Colorectal cancer. BMJ 1997, 314:1882-1885.
57. Casillas S, Pelley RJ, Milsom JW: Adjuvant therapy for colorectal cancer. Present and future perspectives. Dis Colon Rectum 1997, 40:977-992
58. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, et al.: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994, 12:2640-2647.
59. Benson III AB, Catalano PJ, Rao DG, Haller DG, O'Dwyer PJ, Allegra CJ, Johnston PG: Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients with resected colon or advanced colorectal cancer. An ECOG study [abstract 917]. Proc Am Soc Clin Oncol 1997, 16:258a These preliminary data on the role of thymidylate synthase expression in patients who underwent adjuvant chemotherapy with a 5-FU based regimen in the NSABP studies further suggest that this may constitute a prognostic factor of clinical importance.
60. Cunningham D, Zalcberg J, Rath U, Olver I, Van Cutsen E, Svensson C, et al.: Tomudex ZD1694: results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995, 31A:1945-1954.
61. Machover D, Diaz-Rubio E, de Grammont A, Schilf A, Gastiaburu JJ, Briensa S, et al.: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoro-pyrimidines. Ann Oncol 1996, 7:95-98.
62. De Gramont A, Vignoud J, Tournigand C, Louvet C, Andre T, Varette C, et al.: Oxaliplatin with high dose folinic acid and 5-Fluorouracil 48 Hr infusion in pre-treated metastatic colorectal cancer (CRC). Eur J Cancer 1997, 33:214-219.
63. Rothenberg ML, Echardt JR, Burris HA III, Nelson J, Kuhn JG, Chen SF, et al.: Irinotecan (CPT-11) as second-line therapy for patients with 5-FU refractory colorectal cancer [abstract 578]. Proc Am Soc Clin Oncol 1994, 13:198.
64. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al.: Combination phase I study of CPT-11, a new camphotecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11:909-913.